Under construction – not a live service
Sign in

2026-525790-39-00RecruitingPhase 1

A study to investigate the repeat-dose pharmacokinetics of a combined oral contraceptive when given alone and in combination with ganfeborole in female participants of non-childbearing potential.

Source: EU CTIS (euclinicaltrials.eu) · Last updated 7 Oct 2026

Next steps

Status (registry)
Recruiting
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
28 (estimated)
First submitted
31 Mar 2026
Start date
20 Aug 2026
Lead sponsor
Glaxosmithkline Research & Development Limited
Diseases
Tuberculosis
EU CT number
2026-525790-39-00

What you commit to

  • Study type: Interventional · Phase 1
  • Planned participants: 28
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adult women who cannot become pregnant. It studies how a birth control pill behaves in the body alone and together with ganfeborole.

Age
18 years or older
Sex
Women only

Read by machine on 9 Nov 2026.

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Hospital Universitario La PazMadridSpainRecruiting

Are you the coordinator? Confirm the details

This page is information, not medical advice. Discuss any trial with your doctor.